DF/HCC Pipelines in Oncology: Agios
Thursday, March 20 at 12:30pm to 2:00pm
Agios is dedicated to the development of metabolic inhibitors/therapeutic agents, such as AG-221 (IDH2 inhibitor), AG-120 (IDH1 inhibitor) AG-348 (pyruvate kinase R activator), as well as other candidate metabolic cancer targets.
Lunch will be provided at DFCI for the seminar
No recent activity